Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Main project (NSCLC Stage IIIB/C, Stage IV, BSC; 2015-2025): Up to 12000 patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care. NSCLC stage IV (starting 2025): Up to 5000 patients with stage IV NSCLC at the start of first-line systemic therapy. Satellite NSCLC stage I-III: Up to 1600 patients with stage I-III NSCLC at the start of first antitumoral treatment (surgery, radio(chemo)therapy, systemic therapy). Satellite SCLC: Up to 2300 patients with SCLC (limited stage (LD) or extensive stage (ED)), if they are eligible for surgery and/or radio(chemo)therapy and/or systemic therapy, will be recruited (CRISP satellite SCLC patients). Patients will be recruited in up to 220 study sites (certified lung cancer centers, comprehensive cancer centers, hospitals and office-based oncology practices) in Germany.